Arena Pharmaceuticals, Inc. (ARNA) Stock: Do Analysts Think You Should Buy?

Thursday, September 16, 2021 02:10 PM | InvestorsObserver Analysts

Mentioned in this article

Arena Pharmaceuticals, Inc. (ARNA) Stock: Do Analysts Think You Should Buy?

Wall Street is positive on Arena Pharmaceuticals, Inc. (ARNA). On average, analysts give the stock a Strong Buy rating. The average price target is $97.428, which means analysts expect the stock to add by 64.27% over the next twelve months. That average ranking earns the stock an Analyst Rating of 75, which is better than 75% of stocks based on data compiled by InvestorsObserver.

Wall Street analysts are rating ARNA a Strong Buy today. Find out what this means to you and get the rest of the rankings on ARNA!

See Full ARNA Report

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With Arena Pharmaceuticals, Inc. Stock Today?

Arena Pharmaceuticals, Inc. (ARNA) stock is up 0.37% while the S&P 500 is down -0.25% as of 2:08 PM on Thursday, Sep 16. ARNA is higher by $0.22 from the previous closing price of $59.09 on volume of 123,771 shares. Over the past year the S&P 500 has gained 32.03% while ARNA is down -15.15%. ARNA lost -$8.17 per share the over the last 12 months. Click Here to get the full Stock Report for Arena Pharmaceuticals, Inc. stock.